1 / 13

The Generic market @ a cross road

The Generic market @ a cross road. September 2006. The Generic Landscape. Fundamental drivers of growth unchanged. Ageing Population. High healthcare costs. Estimated % of regional population over 60. Total Healthcare Spending, % of GDP. The Generic Landscape. Growing generic

jeslyn
Télécharger la présentation

The Generic market @ a cross road

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Generic market @ a cross road September 2006

  2. The Generic Landscape Fundamental drivers of growth unchanged Ageing Population High healthcare costs Estimated % of regional population over 60 Total Healthcare Spending, % of GDP

  3. The Generic Landscape Growing generic opportunity Revenues Patent Expiries • Large mature markets • Increasing generic penetration • in newer markets $ Bn Patent expiry, 2006 - 10

  4. Increasing Generic Penetration

  5. Generic Market Opportunity Strong generic growth through 2008 78 . 5 80 60 ( US $ Bn ) 43 . 7 2004 40 32 . 5 2008 19 . 8 20 9 . 7 6 . 5 5 . 6 5 . 5 4 . 3 3 . 3 2 . 9 1 . 2 0 Worldwide USA Germany Japan UK France CAGR 2004 - 08 16% 13% 15% 11% 18% 28%

  6. Leading Generic Companies 8000 7000 Annual Sales (US$ Millions 06E) Consolidation to gather momentum 6000 5000 ? 4000 Pliva + ? BRL Watson 3000 + Andrx 2000 1000 0 Teva Sandoz Merck Ranbaxy Mylan Ratiopharm

  7. “Competition is good” – is it now? Really? 2000 2006

  8. Invasion!!! Over a 100 competitors in the US market

  9. A new reality – commodity type market SANDOZ: “We expect prices to fall by at least 10% in 2006”

  10. Emerging Market Generics Competitive Advantages • Low cost – R&D, production facilities. • Technologically advanced – Decades of serving home markets regardless of IP. • Global presence – M&A , organic expansion. • Vertically Integrated – API world leaders. • P4 – concentration on US exclusivity.

  11. Authorized Generics – How Bad Are They?

  12. Biosimilars – The Future?

  13. Biosimilars – Where & When?

More Related